463 related articles for article (PubMed ID: 950366)
1. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome.
Judd HL; Rigg LA; Anderson DC; Yen SS
J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366
[TBL] [Abstract][Full Text] [Related]
2. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
4. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
[TBL] [Abstract][Full Text] [Related]
5. Plasma hormones in clomiphene citrate therapy.
Wu CH
Obstet Gynecol; 1977 Apr; 49(4):443-8. PubMed ID: 857209
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
[TBL] [Abstract][Full Text] [Related]
7. Hormone levels following wedge resection in polycystic ovary syndrome.
Mahesh VB; Toledo SP; Mattar E
Obstet Gynecol; 1978 Jan; 51(1 Suppl):64s-69s. PubMed ID: 144874
[TBL] [Abstract][Full Text] [Related]
8. The effect of ovarian wedge resection and incision on circulating gonadotropin in patients with polycystic ovarian disease.
Tanaka T; Fujimoto S; Kutsuzawa T
Int J Fertil; 1978; 23(2):93-9. PubMed ID: 30730
[TBL] [Abstract][Full Text] [Related]
9. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
Christman GM; Randolph JF; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
[TBL] [Abstract][Full Text] [Related]
11. Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease.
Chang RJ; Mandel FP; Lu JK; Judd HL
J Clin Endocrinol Metab; 1982 Mar; 54(3):490-4. PubMed ID: 6799536
[TBL] [Abstract][Full Text] [Related]
12. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
Wallace EM; Gow SM; Wu FC
J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
[TBL] [Abstract][Full Text] [Related]
13. Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO.
Lobo RA; Granger L; Goebelsmann U; Mishell DR
J Clin Endocrinol Metab; 1981 Jan; 52(1):156-8. PubMed ID: 6778890
[TBL] [Abstract][Full Text] [Related]
14. Effect of gonadotrophin-releasing hormone analogue (GnRH-A) administration on serum gonadotrophin and steroid levels in patients with polycystic ovarian disease.
Mongioi A; Maugeri G; Macchi M; Calogero A; Vicari E; Coniglione F; Aliffi A; Sipione C; D'Agata R
Acta Endocrinol (Copenh); 1986 Feb; 111(2):228-34. PubMed ID: 3082098
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
16. Pituitary-ovarian relationships in polycystic ovary syndrome.
Baird DT; Corker CS; Davidson DW; Hunter WM; Michie EA; Van Look PF
J Clin Endocrinol Metab; 1977 Oct; 45(4):798-801. PubMed ID: 334789
[TBL] [Abstract][Full Text] [Related]
17. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease.
DeVane GW; Czekala NM; Judd HL; Yen SS
Am J Obstet Gynecol; 1975 Feb; 121(4):496-500. PubMed ID: 125040
[TBL] [Abstract][Full Text] [Related]
18. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease.
Steingold KA; Lobo RA; Judd HL; Lu JK; Chang RJ
J Clin Endocrinol Metab; 1986 May; 62(5):1048-51. PubMed ID: 2937800
[TBL] [Abstract][Full Text] [Related]
19. Plasma hormones in human gonadotropin induced ovulation.
Wu CH
Obstet Gynecol; 1977 Mar; 49(3):308-13. PubMed ID: 840459
[TBL] [Abstract][Full Text] [Related]
20. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]